Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024GlobeNewsWire • Tuesday
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyGlobeNewsWire • 04/25/24
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 03/27/24
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 StudiesGlobeNewsWire • 03/27/24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/12/24
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024GlobeNewsWire • 03/05/24
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024GlobeNewsWire • 02/26/24
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024GlobeNewsWire • 02/20/24
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 01/05/24
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)GlobeNewsWire • 12/07/23
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit ProfileGlobeNewsWire • 11/13/23
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)GlobeNewsWire • 11/10/23
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker DataGlobeNewsWire • 11/03/23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/02/23
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558GlobeNewsWire • 10/03/23
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009GlobeNewsWire • 07/19/23
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023GlobeNewsWire • 06/21/23
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023GlobeNewsWire • 06/07/23
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver DiseasesGlobeNewsWire • 05/12/23
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/23